Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues
Ryoko Futai, Michiyo Koyanagi-Aoi, Aito Nakahashi, Daiki Katsura, Manabu Horikawa, Kazumasa Horie, Yoshihiro Kakeji, Yuzo Kodama, Takashi Aoi · 2026
Read Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues by Ryoko Futai, Michiyo Koyanagi-Aoi, Aito Nakahashi, Daiki Katsura, Manabu Horikawa, Kazumasa Horie, Yoshihiro Kakeji, Yuzo Kodama, Takashi Aoi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13476892.txt.
Description
Ryoko Futai and co-authors grow uncommon immune cells from stem cells in 2026 and test them against patient-derived tumors. Gamma-delta T cells kill tumors without needing the usual identity checks that limit other T cells. The lab-grown cells were tried on bowel cancer lines and on organoids grown from patients. Both dish and mouse tests measured killing.
The grown cells killed seventy to ninety percent of targets in dishes across lines and organoids. In mice, local and vein delivery shrank tumors by seventy to one hundred percent. Patient organoids keep tumor traits that cell lines lose, which strengthens the proof. Off-the-shelf cell therapy for solid tumors gains ground.
Catalog record
| CREATOR | Ryoko Futai, Michiyo Koyanagi-Aoi, Aito Nakahashi, Daiki Katsura, Manabu Horikawa, Kazumasa Horie, Yoshihiro Kakeji, Yuzo Kodama, Takashi Aoi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74752 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |